Sign in
TerminatedPhase 1/2

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

Key facts

Who runs it
Institute of Hematology & Blood Diseases Hospital, China
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
6 people enrolled
Started
5 May 2023
Ended
30 Mar 2025
Type of study
Interventional
Treatments tested
  • Selinexor
  • Venetoclax
  • Azacitidine
Record updated
30 May 2025
Why it stopped
The number of participants in the study did not meet expectations

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Newly diagnosed AML patients diagnosed according to WHO standards who are not suitable for the standard induction treatment regimen of cytarabine combined with anthracycline drugs due to age or comorbidities
  • Age ≥ 75 years old, ECOG score 0-2 points; The patient's age range is 18-75 years old, with an ECOG score of 0-3
  • Liver function meets the following criteria: total bilirubin<3 × Upper limit of normal range (ULN) (<75 years old), total bilirubin<1.5 × ULN (≥ 75 years old), AST<3 × ULN and ALT<3 × ULN
  • Renal function meets the following criteria: creatinine clearance rate ≥ 30 mL/min (Cockroft-Gault formula)
  • Expected survival time greater than 6 months

Who cannot take part

  • patient who has received BCL2 inhibitors, demethylation drugs, chemotherapy, CAR-T therapy, or other experimental therapies
  • I underwent major surgery within 4 weeks before the first study medication
  • History of myeloproliferative tumors (MPN)
  • Subjects with unstable or active cardiovascular diseases who meet any of the following criteria:
  • Symptomatic myocardial ischemia
  • Cytogenetic low risk, such as t (8; 21), inv (16), t (16; 16) or t (15; 17)
  • Acute promyelocytic leukemia
  • AML central nervous system (CNS) involvement
  • Pregnancy or lactation period

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a single arm open exploratory clinical trial to evaluate the efficacy and safety of selinexor combined with venetoclax and azacitidine. This study will be divided into two stages: dose increasing stage and dose expanding stage. In the dose-increasing stage, the study induction therapy was designed using a 3+3 design. The induction therapy and consolidation therapy of the subjects will be administered at RP2D doses.

Read full original descriptionShow less

During this study period, there were a total of 4 cycles. The treatment cycle of the subjects will include 2 cycles of induction therapy and up to 2 cycles of consolidation therapy.

In addition, if the subject does not achieve remission (CR/Cr or PR) after 2 cycles of consolidation treatment (at the end of the 4th course), the study will be terminated by the subject, and the clinical doctor will choose the subsequent treatment for the subject based on clinical experience.

The group in the trial

  • selinexor venetoclax AzacitidineTreatment being tested

    In the dose-increasing stage, the subject induction therapy was designed using a 3+3 design. selinexor 60mg QW, 40mg BIW, or 60mg BIW, in combination with venetoclax 100mg d1 200mg d2 400mg d3-28, orally once a day, and azacitidine 75mg/m2, d1-7, subcutaneously. The medication regimen was repeated every 28 days. In this case, RP2D is determined based on MTD, safety, and all other data. During this study period, there were a total of 4 courses. The treatment cycle of the subjects will include 2 cycles of induction therapy and up to 2 cycles of consolidation therapy.

    Treatment: Selinexor, Venetoclax, and Azacitidine

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Exploratory Clinical Study of Selinexor Combined With Venetoclax and Azactidine in the Treatment of Acute Myeloid Leukemia Patients Who Are Not Eligible for Intense Chemotherapy Regimen at Initial Treatment
Record updated
30 May 2025